Early gastric cancer
Conditions
Interventions
Gold Standard:Postoperative Pathological diagnosis (HE staining, immunohistochemistry for CD31 and D2-40)
Index test:Illumina 850K chip
Pyrosequencing
Sponsors
The Second Hospital of Shandong University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: After surgery/ESD treatment, EGC group: 1. First diagnosis of gastric cancer; 2. Gastric cancer is limited to the gastric mucosal layer and submucosa; 3. Failure to receive radiotherapy or chemotherapy before surgery; 4. Postoperative histopathology of the sample showed whether the tumor had vascular invasion and lymphatic vessel invasion. Pre-surgery/ESD treatment EGC group: 1. Individuals with a high suspicion of gastric cancer, but the exact treatment has not yet been determined; 2. Participant has expressed understanding and signed a written informed consent form to participate in the study.
Exclusion criteria
Exclusion criteria: After surgery/ESD treatment, EGC group: 1. Patients diagnosed with other cancers or metastases from other cancers; 2. Patients diagnosed with autoimmune diseases, inflammatory diseases, hematologic diseases, and other infectious diseases; 3. Patients with a family history of gastric cancer. Pre-surgery/ESD treatment EGC group: 1. Patients diagnosed with other cancers or metastases from other cancers; 2. Patients diagnosed with autoimmune diseases, inflammatory diseases, hematologic diseases, and other infectious diseases; 3. Patients with a family history of gastric cancer; 4. Patients with incomplete histopathological information of postoperative samples.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area Under the Curve (AUC);Sensitivity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Specificity;Positive Predictive Value (PPV);Negative Predictive Value (NPV); | — |
Countries
China
Contacts
Public ContactChuanxin Wang
The Second Hospital of Shandong University
Outcome results
None listed